

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Kindstar Globalgene Technology, Inc.
康聖環球基因技術有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 9960)

**FURTHER ANNOUNCEMENT
ON CONNECTED TRANSACTION IN RELATION TO
SUBSCRIPTION OF INTERESTS IN THE FUND**

Reference is made to the announcements of Kindstar Globalgene Technology, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) dated May 23, 2022 (the “**Announcement**”) in relation to subscription of interests in the Fund. Unless otherwise specified, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Board would like to provide additional information in relation to the Subscription as follows:

**THE BACKGROUND AND RELEVANT EXPERIENCE OF THE GENERAL PARTNER/
INVESTMENT ADVISER**

As disclosed in the Announcement, the General Partner is responsible for the management, policies and control of the Fund. The General Partner may cause the Fund to appoint an investment adviser (“**Investment Adviser**”) to provide investment advisory services to the General Partner with respect to the affairs of the Fund. As of the date of this announcement, the General Partner has appointed Panacea Venture Management Company Ltd., a Cayman Islands exempted limited company, to be the Investment Adviser. The Investment Adviser is principally engaged in providing investment advisory services.

As of the date of this announcement, the Investment Adviser is managed by Mr. Huang Zuie-Chin (“**Mr. Huang**”). Mr. Huang is the founding managing partner of Panacea Venture (“**Panacea**”). He has over 30 years of experience in the healthcare industry across Asia and the US. Prior to founding Panacea, Mr. Huang joined Kleiner Perkins Caufield & Byers China in 2011 as a managing partner, focusing on life science investments in the Greater China region. Before that, Mr. Huang was a managing partner at Vivo Ventures and president of Anesiva, a biopharmaceutical company focused on pain-management treatments. Mr. Huang has also held a number of senior positions across business development, marketing, and research and development functions with world leading healthcare companies, including Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb, and ALZA Corp. (acquired by Johnson & Johnson). Mr. Huang holds a master of business administration degree from Stanford Graduate School of Business and a bachelor of science degree in chemical engineering from the University of California, Berkeley.

Please refer to the section headed “Directors and Senior Management” in the Company’s annual report for the year ended December 31, 2021 for the full biography of Mr. Huang.

DETAILS OF THE INVESTMENT MANDATE OF THE FUND, AND THE NATURE OF THE UNDERLYING INVESTMENTS

The Fund, a global venture capital fund, is organized for making investments primarily in emerging, high-potential early and growth stage companies in the fields of biotechnology and pharmaceuticals, medical devices and diagnostics, and healthcare IT and related services, with a view to generating income and capital appreciation.

As the Fund is recently formed and still in the process of fund-raising, no past performance of the Fund is available for disclosure in this announcement.

All information as set out in the Announcement remain unchanged and shall continue to be valid for all purposes, while this announcement is supplemental to and should be read in conjunction with the Announcement.

By order of the Board
Kindstar Globalgene Technology, Inc.
康聖環球基因技術有限公司
HUANG Shiang
Chairman

Hong Kong, May 31, 2022

As of the date of this announcement, the Board comprises Dr. Huang Shiang, Mr. Tu Zanbing and Ms. Chai Haijie as executive Directors, Mr. Huang Zuie-Chin, Mr. Peng Wei and Ms. Huang Lu as non-executive Directors, and Dr. Yao Shanglong, Dr. Xia Xiping and Mr. Gu Huaming as independent non-executive Directors.